Dianthus Therapeutics, Inc. (DNTH)
88.51
-3.30
(-3.59%)
USD |
NASDAQ |
Nov 16, 14:12
Dianthus Therapeutics Profit Margin (Quarterly) : -3.85K% for Sept. 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -3.85K% |
| June 30, 2026 | -6.60K% |
| March 31, 2026 | -8.82K% |
| December 31, 2025 | -22.69K% |
| September 30, 2025 | -9.28K% |
| June 30, 2025 | -16.39K% |
| March 31, 2025 | -2.54K% |
| December 31, 2024 | -2.14K% |
| September 30, 2024 | -1.16K% |
| Date | Value |
|---|---|
| June 30, 2024 | -945.1% |
| March 31, 2024 | -1.57K% |
| December 31, 2023 | -2.31K% |
| September 30, 2023 | -1.60K% |
| June 30, 2023 | -1.15K% |
| March 31, 2023 | -1.49K% |
| December 31, 2022 | -860.9% |
| September 30, 2022 | -663.6% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Xencor, Inc. | 33.84% |
| ACADIA Pharmaceuticals, Inc. | 15.64% |
| Alnylam Pharmaceuticals, Inc. | -- |
| Anika Therapeutics, Inc. | -1.02% |
| Savara, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -21.71% |
| Return on Assets | -20.86% |
| Return on Invested Capital | -21.68% |
| Gross Profit Margin (Quarterly) | 90.99% |
| Operating Margin (Quarterly) | -4.83K% |
| Return on Net Operating Assets | -1.63K% |